Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

PATENTS

Evidence-based obviousness for use in patent prosecution and review

A process for the non-arbitrary determination of obviousness based on examining actual patenting practices of large groups could improve outcomes.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2: The date of first disclosure of a deuterated drug patent application by the peer group.

References

  1. US Patent and Trademark Office. Trial Statistics: IPR, PGR, CBM. Patent Trial and Appeal Board, May 2017, https://www.uspto.gov/sites/default/files/documents/Trial_Statistics_2017–05–31.pdf (2017).

  2. Carter, J. R. Houst. Law Rev. 54, 1315–1348 (2016).

    Google Scholar 

  3. Schuster, W. M. Mich. Telecommun. Technol. Law Rev. 22, 281–286 (2015).

    Google Scholar 

  4. Shepherd, J. NYU J. Intell. Prop. Ent. L. 6, 14–46 (2016).

    Google Scholar 

  5. U.S. Code Title 35—Inter Partes Review, https://www.govinfo.gov/content/pkg/USCODE-2012-title35/pdf/USCODE-2012-title35-partIII-chap31.pdf.

  6. McAllister, R.B. & Vandlen, C.E. Cornell HR Rev. http://digitalcommons.ilr.cornell.edu/chrr/17 (2010).

  7. Mullard, A. Nat. Rev. Drug Discov. 15, 219–221 (2016).

    Article  CAS  Google Scholar 

  8. Schmidt, C. Nat. Biotechnol. 35, 493–494 (2017).

    Article  CAS  Google Scholar 

  9. Timmins, G. S. Expert Opin. Ther. Pat. 24, 1067–1075 (2014).

    Article  CAS  Google Scholar 

  10. Harbeson, S. L. et al. J. Pharmacol. Exp. Ther. 362, 359–367 (2017).

    Article  CAS  Google Scholar 

  11. Srivastava, K. et al. Patient Prefer. Adherence 7, 419–434 (2013).

    PubMed  PubMed Central  Google Scholar 

  12. Reinhold, D.F. US Patent 3,950,411 (1976).

  13. McCarty, L.P. US Patent 4,069,346 (1978).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Graham S. Timmins.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Timmins, G.S. Evidence-based obviousness for use in patent prosecution and review. Nat Biotechnol 37, 997–1000 (2019). https://doi.org/10.1038/s41587-019-0232-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0232-x

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research